NGC Update Service: February 15, 2016

Guideline Summaries

American College of Radiology

• ACR Appropriateness Criteria® acute nonspecific chest pain — low probability of coronary artery disease. This updates a previously published guideline summary.
• ACR Appropriateness Criteria® chronic elbow pain. This updates a previously published guideline summary.
• ACR Appropriateness Criteria® follow-up of malignant or aggressive musculoskeletal tumors. This updates a previously published guideline summary.
• ACR Appropriateness Criteria® radiologic management of hepatic malignancy. This updates a previously published guideline summary.
• ACR Appropriateness Criteria® radiologic management of thoracic nodules and masses. This updates a previously published guideline summary.

Withdrawn Summaries

The summaries listed below have been withdrawn from the NGC Web site because they no longer meet the NGC Inclusion Criteria. See the Guideline Archive for a complete list of guidelines that have been withdrawn from the NGC Web site.

Program in Evidence-based Care

• Adjuvant ovarian ablation in the treatment of premenopausal women with early stage invasive breast cancer.
• Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer.
• First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer.
• Healthy eating, physical activity, and healthy weights guideline for public health in Ontario.
• Imatinib mesylate in the adjuvant treatment of gastrointestinal stromal tumours (GIST).
• PET imaging in colorectal cancer.
• PET imaging in esophageal cancer.
• Primary excision margins and sentinel lymph node biopsy in clinically node-negative cutaneous melanoma of the trunk or extremities: guideline recommendations.
• Psychosocial health care for cancer patients and their families.
• Single-agent interleukin-2 in the treatment of metastatic melanoma: a clinical practice guideline.
• Systemic therapy for advanced gastric cancer.
• Thalidomide in multiple myeloma.
• The role of IMRT in breast cancer.
• The role of IMRT in central nervous system cancer.
• The role of IMRT in gastrointestinal cancers.
• The role of IMRT in gynecologic cancers.
• The role of IMRT in lung cancer.
• The role of IMRT in prostate cancer.
• The role of IMRT in skin cancers.
• The role of IMRT in soft-tissue sarcomas.
• The role of IMRT in thyroid cancers.
• The role of trastuzumab in adjuvant and neoadjuvant therapy in women with HER2/neu-overexpressing breast cancer: a clinical practice guideline.
• Treatment of anemia with erythropoietic agents in patients with cancer – adaption/adoption of ASH-ASCO guidelines.
• Zoledronic acid as adjuvant therapy in combination with adjuvant endocrine therapy for premenopausal women with early-stage hormone receptor positive breast cancer.
• Zoledronic acid for the treatment of bone metastases secondary to renal cell carcinoma.

Royal College of Obstetricians and Gynaecologists

• Amniocentesis and chorionic villus sampling.
• Antenatal corticosteroids to reduce neonatal morbidity and mortality.
• Birth after previous caesarean birth.
• Late intrauterine fetal death and stillbirth.
• Management of HIV in pregnancy.
• Preterm prelabour rupture of membranes.
• The diagnosis and treatment of malaria in pregnancy.
• The management of gestational trophoblastic disease.
• The management of third- and fourth-degree perineal tears.
• The prevention of malaria in pregnancy.
• Thromboembolic disease in pregnancy and the puerperium: acute management.
• Venous thromboembolism and hormonal contraception.